BiotechTube

ACAM3000 MVA Vaccine

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smallpox

Conditions

Smallpox

Trial Timeline

Apr 1, 2004 → Oct 1, 2006

NCT ID
NCT00079820

About ACAM3000 MVA Vaccine

ACAM3000 MVA Vaccine is a phase 1 stage product being developed by Sanofi for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT00079820. Target conditions include Smallpox.

What happened to similar drugs?

3 of 8 similar drugs in Smallpox were approved

Approved (3) Terminated (0) Active (5)
✅Vaccination with ACAM2000Emergent BioSolutionsApproved
✅Tecovirimat + sevelamer carbonate oral tablet + sucroferric oxyhydroxide chewable tablet + calcium acetate oral tablet + Lanthanum Carbonate Chewable TabletSIGA TechnologiesApproved
✅TpoxxSIGA TechnologiesApproved
🔄FD MVA-BNBavarian NordicPhase 3
🔄IMVAMUNE®Bavarian NordicPhase 3
🔄ACAM2000Emergent BioSolutionsPhase 3
🔄tecovirimatSIGA TechnologiesPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00079820Phase 1Completed

Competing Products

20 competing products in Smallpox

See all competitors
ProductCompanyStageHype Score
mRNA-1769ModernaPhase 2
0
Smallpox vaccine, LISTER strain, from chick embryo cellsSanofiPhase 2
35
MVA (smallpox vaccine)SanofiPhase 1
21
MVA Smallpox vaccine + PlaceboSanofiPhase 2
35
ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: DryvaxSanofiPhase 2
27
IMVAMUNE (MVA-BN)Bavarian NordicPhase 2
32
MVA-BNBavarian NordicPhase 1
26
IMVAMUNE®Bavarian NordicPhase 2
32
LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE®Bavarian NordicPhase 2
32
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
32
FD MVA-BNBavarian NordicPhase 3
37
IMVAMUNE®Bavarian NordicPhase 3
37
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
32
MVA-BN® (IMVAMUNE) + PlaceboBavarian NordicPhase 2
32
Elstree-BNBavarian NordicPhase 1
26
ACAM2000Emergent BioSolutionsPhase 3
30
VIGIVEmergent BioSolutionsPre-clinical
23
ACAM2000® smallpox vaccineEmergent BioSolutionsPre-clinical
16
BrincidofovirEmergent BioSolutionsPhase 1
19
Vaccination with ACAM2000Emergent BioSolutionsApproved
33